BioNexus Gene Lab (BGLC) Short Interest Ratio & Short Volume → The #1 Investment of the Decade… (From Porter & Company) (Ad) Free BGLC Stock Alerts $0.57 -0.01 (-1.72%) (As of 05/16/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media BioNexus Gene Lab Short Interest DataCurrent Short Volume176,500 sharesPrevious Short Volume99,700 sharesChange Vs. Previous Month+77.03%Dollar Volume Sold Short$109,412.35Short Interest Ratio / Days to Cover0.1Last Record DateApril 30, 2024Outstanding Shares17,793,000 sharesFloat Size7,020,000 sharesShort Percent of Float2.51%Today's Trading Volume44,692 sharesAverage Trading Volume1,049,590 sharesToday's Volume Vs. Average4% Short Selling BioNexus Gene Lab ? Sign up to receive the latest short interest report for BioNexus Gene Lab and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatBGLC Short Interest Over TimeBGLC Days to Cover Over TimeBGLC Percentage of Float Shorted Over Time Ad Porter & CompanyThe #1 Investment of the Decade… Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.To get all the details of this controversial tech – click here now. BioNexus Gene Lab Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2024176,500 shares $109,412.35 +77.0%2.5%0.1 $0.62 4/15/202499,700 shares $61,983.49 +129.7%1.4%0.1 $0.62 3/31/202443,400 shares $30,640.40 +115.9%0.6%0 $0.71 3/15/202420,100 shares $14,381.55 -60.0%0.3%0 $0.72 2/29/202450,300 shares $28,268.60 -94.6%0.7%0 $0.56 2/15/2024922,200 shares $1.05 million +885.3%12.1%0.3 $1.14 1/31/202493,600 shares $43,926.48 No Change1.2%0 $0.47 7/15/202320,600 shares $22,248.00 +4,020.0%N/A0 $1.08 BGLC Short Interest - Frequently Asked Questions What is BioNexus Gene Lab's current short interest? Short interest is the volume of BioNexus Gene Lab shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 176,500 shares of BGLC short. 2.51% of BioNexus Gene Lab's shares are currently sold short. Learn More on BioNexus Gene Lab's current short interest. What is a good short interest percentage for BioNexus Gene Lab? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.51% of BioNexus Gene Lab's floating shares are currently sold short. Is BioNexus Gene Lab's short interest increasing or decreasing? BioNexus Gene Lab saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 176,500 shares, an increase of 77.0% from the previous total of 99,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is BioNexus Gene Lab's float size? BioNexus Gene Lab currently has issued a total of 17,793,000 shares. Some of BioNexus Gene Lab's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. BioNexus Gene Lab currently has a public float of 7,020,000 shares. How does BioNexus Gene Lab's short interest compare to its competitors? 2.51% of BioNexus Gene Lab's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to BioNexus Gene Lab: OpGen, Inc. (1.59%), Psychemedics Co. (0.35%), DermTech, Inc. (10.13%), Exagen Inc. (0.05%), Biotricity, Inc. (7.35%), Moleculin Biotech, Inc. (1.45%), Aeterna Zentaris Inc. (0.34%), BioCardia, Inc. (0.98%), Guardion Health Sciences, Inc. (14.33%), PHAXIAM Therapeutics S.A. (0.01%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short BioNexus Gene Lab stock? Short selling BGLC is an investing strategy that aims to generate trading profit from BioNexus Gene Lab as its price is falling. BGLC shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against BioNexus Gene Lab? A short squeeze for BioNexus Gene Lab occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BGLC, which in turn drives the price of the stock up even further. How often is BioNexus Gene Lab's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BGLC, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: OPGN Short Squeeze PMD Short Squeeze DMTK Short Squeeze XGN Short Squeeze BTCY Short Squeeze MBRX Short Squeeze AEZS Short Squeeze BCDA Short Squeeze GHSI Short Squeeze PHXM Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BGLC) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe 1,000X Crypto PlaybookTrue Market InsidersCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMost important medical advance in 100 yearsThe Oxford ClubBill Clinton Backing Biden Replacement???The Freeport SocietyCharles Payne Demystifies OptionsUnstoppable ProsperityWhy Is Gold On a MASSIVE rally? Huge Alerts